SpringerLink
Log in

Fingolimod-associated progressive multifocal leukoencephalopathy in a multiple sclerosis patient with a good response to filgrastim

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Cortese I, Reich DS, Nath A (2021) Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol 17:37–51. https://doi.org/10.1038/s41582-020-00427-y

    Article  PubMed  Google Scholar 

  2. Sriwastava S, Kataria S, Srivastava S, Kazemlou S, Gao S, Wen S, Saber H, Tripathi R, Sheikh Z, Peterson S, Gwinn R, Bernitsas E (2021) Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: a systematic review and meta-analysis. J Neuroimmunol 360:577721. https://doi.org/10.1016/j.jneuroim.2021.577721

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Möhn N, Grote-Levi L, Hopfner F, Eiz-Vesper B, Maecker-Kolhoff B, Warnke C, Sühs K-W, Wattjes MP, Höglinger GU, Skripuletz T (2022) Innovative therapeutic concepts of progressive multifocal leukoencephalopathy. J Neurol 269:2403–2413. https://doi.org/10.1007/s00415-021-10952-5

    Article  PubMed  PubMed Central  Google Scholar 

  4. Stefoski D, Balabanov R, Waheed R, Ko M, Koralnik IJ, Morales FS (2019) Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol 6:923–931. https://doi.org/10.1002/acn3.776

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, Dong VM, Merschhemke M (2018) Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology 90:E1815–E1821. https://doi.org/10.1212/wnl.0000000000005529

    Article  PubMed  PubMed Central  Google Scholar 

  6. Dong-Si T, Gheuens S, Gangadharan A et al (2015) Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J NeuroVirology 21:637–644. https://doi.org/10.1007/s13365-015-0316-4

    Article  CAS  Google Scholar 

  7. Sinnecker T, Hadisurya J, Schneider-Hohendorf T et al (2019) Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data. BMC Neurol 19:190. https://doi.org/10.1186/s12883-019-1407-2

    Article  PubMed  PubMed Central  Google Scholar 

  8. Mickeviciene D, Baltusiene A, Afanasjeva B, Afanasjevas D, Gleizniene R, Rastenyte D, Berger JR (2022) Progressive multifocal leukoencephalopathy or immune reconstitution inflammatory syndrome after fingolimod cessation? A case report. BMC Neurol 22:306. https://doi.org/10.1186/s12883-022-02839-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Jamilloux Y, Kerever S, Ferry T, Broussolle C, Honnorat J, Sève P (2016) Treatment of progressive multifocal leukoencephalopathy with mirtazapine. Clin Drug Investig 36:783–789. https://doi.org/10.1007/s40261-016-0433-8

    Article  CAS  PubMed  Google Scholar 

  10. Clifford DB, Nath A, Cinque P, Brew BJ, Zivadinov R, Gorelik L, Zhao Z, Duda P (2013) A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J NeuroVirology 19:351–358. https://doi.org/10.1007/s13365-013-0173-y

    Article  CAS  Google Scholar 

  11. Bernard-Valnet R, Koralnik IJ, Du Pasquier R (2021) Advances in treatment of progressive multifocal leukoencephalopathy. Ann Neurol 90:865–873. https://doi.org/10.1002/ana.26198

    Article  PubMed  PubMed Central  Google Scholar 

  12. Barritt AW, Das E, Morley N, Seymour M, Saha R, Vera J, Vundavalli S, Dizdarevic S, Nicholas R, Berger JR, Fisniku LK (2022) Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis. Mult Scler 29:301–306. https://doi.org/10.1177/13524585221137279

    Article  PubMed  Google Scholar 

  13. Roos-Weil D, Weiss N, Guihot A et al (2021) Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: a new gold standard? J Neurol 268:2458–2465. https://doi.org/10.1007/s00415-021-10414-y

    Article  CAS  PubMed  Google Scholar 

  14. Mehta HM, Malandra M, Corey SJ (2015) G-CSF and GM-CSF in neutropenia. J Immunol 195:1341–1349. https://doi.org/10.4049/jimmunol.1500861

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank the patient and her relatives for giving permission to publish this information. We thank Susana Pobla for the technical support. We thank CERCA Programme/Generalitat de Catalunya for institutional support.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Author information

Authors and Affiliations

  1. Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge - IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain

    Paula Lombardo-del Toro, Pablo Arroyo, Raquel Tena-Cucala, Laura Bau, Elisabet Matas, Albert Muñoz-Vendrell, Antonio Martínez-Yélamos, Sergio Martínez-Yélamos & Lucía Romero-Pinel

  2. Department of Neurology, Hospital Residència Sant Camil - Consorci Sanitari Alt Penedès-Garraf, Sant Pere de Ribes, Barcelona, Spain

    Irene Bragado-Trigo

  3. Neuro-Oncology Unit, Hospital Universitari de Bellvitge-Institut Català d’Oncologia L’Hospitalet, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain

    Marta Simó

  4. Department of Neuroradiology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain

    Albert Pons-Escoda

  5. Departament de Ciències Clíniques, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain

    Antonio Martínez-Yélamos & Sergio Martínez-Yélamos

Authors
  1. Paula Lombardo-del Toro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Irene Bragado-Trigo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pablo Arroyo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Raquel Tena-Cucala
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Laura Bau
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elisabet Matas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Albert Muñoz-Vendrell
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marta Simó
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Albert Pons-Escoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Antonio Martínez-Yélamos
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Sergio Martínez-Yélamos
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Lucía Romero-Pinel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lucía Romero-Pinel.

Ethics declarations

Conflicts of interest

Paula Lombardo-del Toro received funding for travel and congress attendance from Novartis and Lilly. Irene Bragado-Trigo, Pablo Arroyo, Raquel Tena-Cucala, Laura Bau, Elisabet Matas, Albert Muñoz-Vendrell, Antonio Martínez-Yélamos, Sergio Martínez-Yélamos and Lucía Romero-Pinel received honorarium for participating on advisory boards and for collaborations as consultants and for their work on scientific communications; they also received research support as well as funding for travel and congress-attending expenses from Roche, Biogen Idec, Novartis, TEVA, Merck, Genzyme, Sanofi, Bayer, Almirall, Horizon and Celgene. Marta Simó and Albert Pons-Escoda declare nothing to disclose.

Ethical approval

Ethics Committee approval was not necessary.

Consent for publish

Written informed consent was obtained from the patient and her relatives before publication.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lombardo-del Toro, P., Bragado-Trigo, I., Arroyo, P. et al. Fingolimod-associated progressive multifocal leukoencephalopathy in a multiple sclerosis patient with a good response to filgrastim. J Neurol 270, 5196–5200 (2023). https://doi.org/10.1007/s00415-023-11865-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-023-11865-1

Search

Navigation